ATLAS 2
- 13,570 participants
- 8 sites in New Zealand
- 800 sites globally
ATLAS ACS 2 TIMI 51 (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)
A randomised, double-blind, placebo-controlled, event-driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome.
This is a randomised, double-blind, placebo-controlled, event driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome. The purpose is to determine whether Rivaroxaban in addition to standard care reduces the risk of the composite cardiovascular (CV) death, myocardial infarction (MI) or stroke in participants with a recent ACS compared with placebo in addition to standard care.